The FDA approved La Jolla Pharmaceutical’s Giapreza (angiotensin II), an injectable drug intended to treat dangerously low blood pressure.
The drug increases blood pressure in adults with septic shock or other distributive shock conditions. The FDA based the approval on a clinical trial of 321 patients with shock and critically low blood pressure and found it increased blood pressure when used with conventional treatments.
The drug had previously received a priority review. The FDA warned the drug can cause dangerous blood clots. Prophylactic treatments should be used in these cases.